Cargando…

Development of biosimilars in an era of oncologic drug shortages

Acute and chronic shortages of various pharmaceuticals and particularly of sterile injectable products are being reported on a global scale, prompting evaluation of more effective strategies to manage current shortages and development of new, high-quality pharmaceutical products to mitigate the risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Edward, Subramanian, Janakiraman, Anderson, Scott, Thomas, Dolca, McKinley, Jason, Jacobs, Ira A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484646/ https://www.ncbi.nlm.nih.gov/pubmed/26150698 http://dx.doi.org/10.2147/DDDT.S75219

Ejemplares similares

Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015)

Drug tendering: drug supply and shortage implications for the uptake of biosimilars
por: Dranitsaris, George, et al.
Publicado: (2017)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
por: Subramanian, Janakiraman, et al.
Publicado: (2017)

Oncology Drug Shortages in America
por: Vogel, Wendy H., et al.
Publicado: (2012)

The Continuing Impact of Oncology Drug Shortages
por: Viale, Pamela Hallquist
Publicado: (2013)

Statistical Primer on Biosimilar Clinical Development
por: Isakov, Leah, et al.
Publicado: (2016)

Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology
por: Tinsley, Sara M., et al.
Publicado: (2018)

Biosimilars in oncology
por: Tabernero, Josep
Publicado: (2018)

Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future
por: Carrascosa, Jose-Manuel, et al.
Publicado: (2018)

Evaluating imbalances of adverse events during biosimilar development
por: Vana, Alicia M., et al.
Publicado: (2016)

Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
por: Scheinberg, Morton, et al.
Publicado: (2018)

Oncology biosimilars: New developments and future directions
por: Bachu, Rinda Devi, et al.
Publicado: (2022)

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)

Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser, John RP, et al.
Publicado: (2017)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects
por: Declerck, Paul, et al.
Publicado: (2017)

Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars
por: Stebbing, Justin, et al.
Publicado: (2020)

Preparing for the incoming wave of biosimilars in oncology
por: Wolff-Holz, Elena, et al.
Publicado: (2018)

Healthcare policy changes in an era of health workforce shortage
por: Angel, Yoel, et al.
Publicado: (2023)

An appraisal of drug development timelines in the Era of precision oncology
por: Jardim, Denis Leonardo, et al.
Publicado: (2016)

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology
por: Giuliani, Rosa, et al.
Publicado: (2019)

Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2017)

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
por: Rosen, Lee S., et al.
Publicado: (2017)

Correction: Preparing for the incoming wave of biosimilars in oncology
Publicado: (2018)

Barriers to Oncology Biosimilars Uptake in the United States
por: Nabhan, Chadi, et al.
Publicado: (2018)

The role of biosimilars in value-based oncology care
por: Patel, Kashyap B, et al.
Publicado: (2018)

Current and future roles of biosimilars in oncology practice
por: Konstantinidou, Sofia, et al.
Publicado: (2020)

Biosimilars in Oncology: Latest Trends and Regulatory Status
por: Joshi, Deeksha, et al.
Publicado: (2022)

Era of biosimilars in rheumatology: reshaping the healthcare environment
por: Smolen, Josef S, et al.
Publicado: (2019)

Food Decisions of Low-Income Families in the Era of COVID-19: A Qualitative Exploration
por: Spyreli, Eleni, et al.
Publicado: (2021)

The BCG Shortage
por: Messing, Edward M.
Publicado: (2017)

Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations
por: Barry, Elly, et al.
Publicado: (2021)

Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
por: Monk, Bradley J., et al.
Publicado: (2017)

Presently available biosimilars in hematology-oncology: G-CSF
por: Gascon, Pere
Publicado: (2012)

Biosimilar agents in oncology/haematology: from approval to practice
por: Niederwieser, Dietger, et al.
Publicado: (2011)

Biosimilars in the United States: Considerations for Oncology Advanced Practitioners
por: Mayden, Kelley D., et al.
Publicado: (2015)

Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner
por: Campen, Christopher J.
Publicado: (2017)

Can biosimilars help achieve the goals of US health care reform?
por: Boccia, Ralph, et al.
Publicado: (2017)

Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey
por: Monk, Bradley J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ldbm5git1025gr03vejldoruco